Sotera Health Co
$ 15.81
1.48%
27 Apr - close price
- Market Cap 4,442,738,000 USD
- Current Price $ 15.81
- High / Low $ 15.86 / 15.60
- Stock P/E 57.70
- Book Value 2.13
- EPS 0.27
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.15 %
- 52 Week High 19.85
- 52 Week Low 10.68
About
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
Analyst Target Price
$20.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-04 | 2025-08-08 | 2025-04-30 | 2025-02-25 | 2024-11-05 | 2024-08-05 | 2024-05-02 | 2024-02-27 | 2023-11-01 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 0.26 | 0.26 | 0.2 | 0.14 | 0.21 | 0.17 | 0.19 | 0.13 | 0.26 | 0.21 | 0.21 | 0.13 |
| Estimated EPS | 0.2422 | 0.2167 | 0.17 | 0.1218 | 0.2019 | 0.18 | 0.16 | 0.13 | 0.26 | 0.2 | 0.18 | 0.14 |
| Surprise | 0.0178 | 0.0433 | 0.03 | 0.0182 | 0.0081 | -0.01 | 0.03 | 0 | 0 | 0.01 | 0.03 | -0.01 |
| Surprise Percentage | 7.3493% | 19.9815% | 17.6471% | 14.9425% | 4.0119% | -5.5556% | 18.75% | 0% | 0% | 5% | 16.6667% | -7.1429% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SHC
2026-04-24 08:10:00
This article identifies three healthcare stocks—Sotera Health (SHC), Acadia Healthcare (ACHC), and Bruker (BRKR)—that are currently underperforming and may not be good investment choices. The author highlights concerns such as slow revenue growth, declining profitability, and increased capital intensity for these companies. Each stock's financial metrics and market cap are provided to support the recommendation to avoid them.
2026-04-21 12:09:06
Sotera Health (SHC) is scheduled to release its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026, for the period ending March 31, 2026. The company will also host a conference call at 9:00 a.m. EDT on the same day to discuss its operating and financial performance. A live webcast and accompanying materials will be available via its investor relations website, with a replay accessible later that day.
2026-04-21 12:09:06
Sotera Health Company (Nasdaq: SHC) has announced that it will release its financial results for the first-quarter ended March 31, 2026, before the market opens on Tuesday, May 5, 2026. Management will host a conference call at 9:00 a.m. EDT on the same day to discuss the results. A live webcast and accompanying materials will be available on the company's Investor Relations website.
2026-04-21 07:46:00
Sotera Health Company (Nasdaq: SHC) announced its plan to release first-quarter 2026 financial results on Tuesday, May 5, 2026, before market open. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the results. A live webcast and accompanying materials will be available via the Investor Relations section of the Company's website.
2026-04-16 14:10:02
Insiders at Sotera Health have sold US$14 million worth of stock over the past year, with no insider purchases recorded. This significant selling activity, particularly by the CEO and other executives, suggests that some insiders believe the stock price might be overvalued or that future performance could be weaker. While insider selling shouldn't be the sole factor in investment decisions, it can signal a lack of confidence and warrants further investigation into the company's fundamentals.
2026-04-14 22:40:23
Barclays has reiterated its Buy rating for Sotera Health Company (SHC.US) but has lowered its target price to $18 from the previous $20. This adjustment reflects an updated valuation while maintaining a positive outlook on the company's stock.
